Allogeneic Cell Therapy Market Report 2026

The allogeneic cell therapy market size has grown rapidly in recent years. It will grow from $1.2 billion in 2025 to $1.34 billion in 2026 at a compound annual growth rate (CAGR) of 11.5%. The growth in the historic period can be attributed to limited availability of allogeneic cell therapy products, early-stage clinical trials expansion, increasing hematological disorder prevalence, growing hospital adoption of cell therapies, reliance on donor cell banks.

The allogeneic cell therapy market size is expected to see rapid growth in the next few years. It will grow to $1.97 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to advancements in stem cell and immune cell engineering, expansion of dermatological and other therapeutic applications, increasing investment in cell therapy manufacturing facilities, collaborations between hospitals and biotech firms, adoption of automated cell processing technologies. Major trends in the forecast period include increasing adoption of stem cell therapies, rising focus on t-cell and nk cell therapies, expansion of ipsc-based therapeutic applications, growing demand for personalized cell therapy treatments, enhanced regulatory oversight and safety standards.

The increasing prevalence of chronic diseases is expected to drive the growth of the allogeneic cell therapy market. Chronic disease is a long-term condition that typically requires ongoing medical care and can affect daily activities or overall quality of life. The rise in chronic diseases is attributed to changes in lifestyle, genetic factors, and exposure to chemicals, toxins, and environmental pollutants. Allogeneic cell therapy has significant potential for treating a wide range of chronic conditions by using healthy donor cells to repair, replace, or modulate dysfunctional cells or tissues in the recipient. For instance, in January 2023, according to the National Center for Biotechnology Information (NCBI), a US-based medical library, the number of people aged 50 and above with one or more chronic illnesses is projected to increase by 99.5% by 2050, rising from 71.52 million in 2020 to 142.66 million. Therefore, the growing prevalence of chronic diseases is driving the expansion of the allogeneic cell therapy market.

Major companies in the allogeneic cell therapy market are concentrating on developing innovative solutions, such as cell processing platforms, to enhance their market position. Cell processing platforms consist of systems and technologies used to prepare and manipulate cells for therapeutic purposes, including isolation, purification, expansion, modification, and quality control to ensure cells are clinically suitable. For instance, in March 2024, Getinge, a Sweden-based healthcare company, partnered with CellRev, a UK-based biotechnology firm, to launch Livit ACE, a platform for continuous cell processing (Adherent Cell Expansion). This advanced platform combines automation and bioprocessing technologies to greatly improve the efficiency and scalability of cell production. Its key features include cutting-edge cell isolation and purification systems for high cell purity and viability, robust expansion capabilities to generate large quantities of therapeutic cells, precise genetic modification tools for targeted cell engineering, and strict quality control measures to ensure the safety and effectiveness of the cell products.

In February 2024, AstraZeneca, a UK-based pharmaceutical company specializing in oncology and rare diseases, acquired Gracell Biotechnologies for an undisclosed sum. Through this acquisition, AstraZeneca aims to strengthen its presence in oncology and rare diseases by incorporating Gracell Biotechnologies’ advanced cell therapy expertise, potentially accelerating the development of novel treatments for complex cancers and other serious conditions. Gracell Biotechnologies is a China-based company that provides allogeneic cell therapy.

Major companies operating in the allogeneic cell therapy market are Novartis AG, Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, Bluebird Bio Inc., Poseida Therapeutics Inc., Fate Therapeutics Inc., Fortress Biotech Inc., Sorrento Therapeutics Inc., Eureka Therapeutics Inc., Juno Therapeutics Inc., Adaptimmune Therapeutics plc, Cellectis SA, Ziopharm Oncology Inc., Allogene Therapeutics Inc., Century Therapeutics Inc., Autolus Therapeutics plc, Bellicum Pharmaceuticals Inc., Celyad SA, TILT Biotherapeutics Ltd., CRISPR Therapeutics AG.

North America was the largest region in the allogeneic cell therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the allogeneic cell therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the allogeneic cell therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the allogeneic cell therapy market by increasing costs for imported stem cell products, reagents, and bioprocessing equipment. Segments such as hematopoietic stem cells, mesenchymal stem cells, and t-cell therapies are most affected, with north america, europe, and asia-pacific regions experiencing higher procurement costs. These tariffs have slowed adoption and increased research expenses. However, they have also encouraged local production, innovation in cell therapy manufacturing, and regional self-sufficiency in advanced therapeutics.

The allogeneic cell therapy market research report is one of a series of new reports that provides allogeneic cell therapy market statistics, including allogeneic cell therapy industry global market size, regional shares, competitors with a allogeneic cell therapy market share, detailed allogeneic cell therapy market segments, market trends and opportunities, and any further data you may need to thrive in the allogeneic cell therapy industry. This allogeneic cell therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Allogeneic cell therapy is a treatment in which cells are collected from a donor and used to treat a different individual (the recipient). These therapies are intended to replace or repair damaged tissues, modulate immune responses, or treat conditions such as cancer, genetic disorders, and autoimmune diseases.

The main categories of allogeneic cell therapy are stem cell therapies and non-stem cell therapies. Stem cell therapies involve the use of stem cells to repair, regenerate, or replace damaged tissues or organs to prevent or treat various diseases and conditions. The therapeutic areas include hematological disorders, dermatological disorders, and other conditions, with end-users such as hospitals, specialty clinics, and research organizations.

The allogeneic cell therapy market includes revenues earned by entities through induced pluripotent stem cell therapy, hematopoietic stem cell transplantation, mesenchymal stem cell (MSC) therapy, induced pluripotent stem cell (IPSC) therapy and chimeric antigen receptor T cell therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.